A Macromolecular Treatment for Ischemic Stroke

缺血性中风的大分子治疗

• 批准号: 6883114
• 负责人: Bashir A. ZIKRIA
• 金额: $ 11.16万
• 依托单位: BIOPHYZICA, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-03-02 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6883114
• 关键词: antioxidants; ascorbate; brain disorder chemotherapy; cats; cerebral ischemia /hypoxia; disease /disorder model; macromolecule; nonhuman therapy evaluation; reperfusion; starch; stroke; stroke therapy; therapy design /development; vascular endothelium

DESCRIPTION (provided by applicant): Stroke accounts for about 1 of every 14 deaths in the United States making it the third leading cause of death. It is also the number one cause of disability, with more than 3 million people currently living with permanent physical and mental impairment from brain damage caused by stroke. BioPhyZica has developed a treatment, known as HES-Z + VitC, for treating capillary leak, edema, and reperfusion injury caused by ischemic stroke. HES-Z + VitC consists of a solution of hydroxyethyl starch (HES) molecules in a specific molecular weight range in combination with an antioxidant additive, ascorbic acid, hereafter referred to as HES-Z + VitC. The hydroxyethyl starch component provides a biophysical action of sealing at capillary endothelial gaps (pores) that develop after stroke, while the antioxidant enhances the overall efficacy by reducing reperfusion injury. The goal of this Phase I STTR research is to demonstrate, in an animal model, that HES-Z + VitC can reduce the neurological deficit after ischemic stroke.

描述（由申请人提供）：在美国，每 14 例死亡中就有 1 例死于中风，使其成为第三大死因。它也是导致残疾的第一大原因，目前有超过 300 万人因中风造成的脑损伤而遭受永久性的身体和精神损伤。 BioPhyZica 开发了一种名为 HES-Z + VitC 的治疗方法，用于治疗缺血性中风引起的毛细血管渗漏、水肿和再灌注损伤。 HES-Z + VitC 由特定分子量范围的羟乙基淀粉 (HES) 分子与抗氧化添加剂抗坏血酸的溶液组成，以下称为 HES-Z + VitC。羟乙基淀粉成分具有密封中风后形成的毛细血管内皮间隙（孔隙）的生物物理作用，而抗氧化剂则通过减少再灌注损伤来增强整体功效。这项 I 期 STTR 研究的目标是在动物模型中证明 HES-Z + VitC 可以减轻缺血性中风后的神经功能缺损。